Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Celexa

Executive Summary

Citalopram co-promotion agreement with Warner-Lambert will be terminated immediately, Forest announces May 12. Forest will pay Warner-Lambert $14 mil. to terminate the agreement and Warner-Lambert will be excluded from any profits recorded after April 30. Forest reported earlier in May that its sales force has been expanded from 850 to 1,425 representatives, resulting in a decrease of net income for the quarter ending March 31. Warner-Lambert's merger partner Pfizer markets the competing antidepressant Zoloft. The termination agreement contains provisions "limiting Warner-Lambert employees previously involved in marketing or selling Celexa from marketing or selling" Zoloft for a specified period of time, Forest said

You may also be interested in...



Forest Aerobid Non-CFC Asthma Inhaler Launch Expected In Fall, C0O Says

Forest will launch its non-CFC version of the prescription asthma inhaler Aerobid (flunisolide) this fall, President and Chief Operating Officer Kenneth Goodman told analysts on a conference call Jan. 16.

Forest Aerobid Non-CFC Asthma Inhaler Launch Expected In Fall, C0O Says

Forest will launch its non-CFC version of the prescription asthma inhaler Aerobid (flunisolide) this fall, President and Chief Operating Officer Kenneth Goodman told analysts on a conference call Jan. 16.

Forest Celexa Sales Reach $150 Mil. For Quarter; Sales Support Steps Up

Forest's internal sales effort for the antidepressant Celexa has exceeded the peak sales effort during the co-promotion period with Warner-Lambert, the company maintains.

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel